Published in J Virol on September 01, 2002
B cells in HIV infection and disease. Nat Rev Immunol (2009) 4.73
Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. J Allergy Clin Immunol (2008) 2.01
DC-SIGN on B lymphocytes is required for transmission of HIV-1 to T lymphocytes. PLoS Pathog (2006) 1.25
HIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites. HIV AIDS (Auckl) (2010) 0.94
HIV-1 Trans Infection of CD4(+) T Cells by Professional Antigen Presenting Cells. Scientifica (Cairo) (2013) 0.93
Epstein-Barr virus-driven lymphomagenesis in the context of human immunodeficiency virus type 1 infection. Front Microbiol (2013) 0.82
Direct phenotypical and functional dysregulation of primary human B cells by human immunodeficiency virus (HIV) type 1 in vitro. PLoS One (2012) 0.78
Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment. AIDS Patient Care STDS (2016) 0.75
CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res (1994) 392.47
The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol (1987) 266.90
MODELTEST: testing the model of DNA substitution. Bioinformatics (1998) 101.19
HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature (1993) 15.54
Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science (1993) 8.49
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A (1999) 5.25
Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol (1993) 5.17
Visualization of specific B and T lymphocyte interactions in the lymph node. Science (1998) 5.04
Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med (2000) 4.83
Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol (1999) 4.66
Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J Virol (1994) 4.35
Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol (1996) 3.48
Follicular dendritic cells and human immunodeficiency virus infectivity. Nature (1995) 3.22
A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes. J Virol Methods (1994) 3.13
A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J Virol (2000) 2.68
Evolutionary variants of the human immunodeficiency virus type 1 V3 region characterized by using a heteroduplex tracking assay. J Virol (1997) 2.04
Genetic subtyping of human immunodeficiency virus using a heteroduplex mobility assay. PCR Methods Appl (1995) 1.96
B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells. J Exp Med (2000) 1.79
Prolonged antigen half-life in the lymphoid follicles of specifically immunized mice. Immunology (1979) 1.57
Tracking changes in HIV-1 envelope quasispecies using DNA heteroduplex analysis. Methods (1997) 1.50
Binding of human immunodeficiency virus type-1 to follicular dendritic cells in vitro is complement dependent. J Immunol (1993) 1.45
Effects of genital tract inflammation on human immunodeficiency virus type 1 V3 populations in blood and semen. J Virol (2000) 1.38
Effect of immune activation on the dynamics of human immunodeficiency virus replication and on the distribution of viral quasispecies. J Virol (1998) 1.30
Dissociation of HIV-1 from follicular dendritic cells during HAART: mathematical analysis. Proc Natl Acad Sci U S A (1999) 1.27
Patterns of changes in human immunodeficiency virus type 1 V3 sequence populations late in infection. J Virol (2000) 1.21
Follicular dendritic cells (FDC) in retroviral infection: host/pathogen perspectives. Immunol Rev (1997) 1.16
Detachment of human immunodeficiency virus type 1 from germinal centers by blocking complement receptor type 2. J Virol (2000) 1.11
Immune complexes containing human immunodeficiency virus type 1 primary isolates bind to lymphoid tissue B lymphocytes and are infectious for T lymphocytes. J Virol (2000) 1.08
Cellular interactions in the germinal center: role of adhesion receptors and significance for the pathogenesis of AIDS and malignant lymphoma. Immunol Rev (1992) 1.07
HIV envelope induces a cascade of cell signals in non-proliferating target cells that favor virus replication. Proc Natl Acad Sci U S A (2002) 17.22
Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis (2008) 11.01
An assessment of interactions between global health initiatives and country health systems. Lancet (2009) 10.53
HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol (2002) 10.37
CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med (2006) 10.34
HIV preferentially infects HIV-specific CD4+ T cells. Nature (2002) 9.28
The challenge of emerging and re-emerging infectious diseases. Nature (2004) 8.94
New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (2003) 8.25
Universal voluntary testing and treatment for prevention of HIV transmission. JAMA (2009) 7.20
Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med (2013) 6.63
Rapid expansion of the health workforce in response to the HIV epidemic. N Engl J Med (2007) 6.34
Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol (2006) 6.30
Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med (2008) 5.94
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med (2011) 5.21
Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med (2008) 5.14
HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol (2008) 5.01
The 1918 influenza pandemic: insights for the 21st century. J Infect Dis (2007) 4.99
Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis (2008) 4.86
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog (2007) 4.82
B cells in HIV infection and disease. Nat Rev Immunol (2009) 4.73
Medicine. The need for a global HIV vaccine enterprise. Science (2003) 4.70
Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med (2011) 4.68
Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science (2007) 4.60
Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol (2003) 4.56
AIDS: lessons learnt and myths dispelled. Lancet (2009) 4.03
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85
The research agenda of the National Institute of Allergy and Infectious Diseases for antimicrobial resistance. J Infect Dis (2008) 3.84
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature (2012) 3.83
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA (2013) 3.82
An HIV vaccine--evolving concepts. N Engl J Med (2007) 3.78
HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest (2005) 3.62
The persistent legacy of the 1918 influenza virus. N Engl J Med (2009) 3.58
Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis (2007) 3.50
Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci U S A (2003) 3.47
HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science (2010) 3.29
Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS (2010) 3.26
Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol (2005) 3.23
Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: a systematic review and meta-analysis. AIDS (2013) 3.17
The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol (2008) 2.85
Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol (2005) 2.82
Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A (2005) 2.80
Pervasive genomic recombination of HIV-1 in vivo. Genetics (2004) 2.79
Emerging infections: a perpetual challenge. Lancet Infect Dis (2008) 2.75
Central role of reverting mutations in HLA associations with human immunodeficiency virus set point. J Virol (2008) 2.72
Virus population homogenization following acute human immunodeficiency virus type 1 infection. J Virol (2002) 2.71
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med (2011) 2.71
Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm Rep (2002) 2.70
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res (2011) 2.64
Evaluation of initial CD4+ T cell counts in individuals with newly diagnosed human immunodeficiency virus infection, by sex and race, in urban settings. J Infect Dis (2002) 2.57
Influenza vaccines for the future. N Engl J Med (2010) 2.54
Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7. Proc Natl Acad Sci U S A (2006) 2.54
Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol (2003) 2.53
Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci U S A (2003) 2.51
IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood (2009) 2.50
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther (2011) 2.50
Selection on the human immunodeficiency virus type 1 proteome following primary infection. J Virol (2006) 2.48
Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One (2010) 2.48
Cellular gene expression upon human immunodeficiency virus type 1 infection of CD4(+)-T-cell lines. J Virol (2003) 2.46
Dengue and hemorrhagic fever: a potential threat to public health in the United States. JAMA (2008) 2.45
Development of effective vaccines against pandemic influenza. Immunity (2006) 2.45
Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog (2013) 2.44
Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area. J Immunol (2009) 2.43
Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis (2011) 2.40
Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. PLoS One (2011) 2.36
Pathogenic mechanisms of HIV disease. Annu Rev Pathol (2011) 2.36
Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog (2009) 2.36
Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med (2002) 2.36
Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J Virol (2003) 2.36
Phylogenetic dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 Gag. PLoS Comput Biol (2008) 2.32
The genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α (4) β(7) +/CD4+ T cells as key targets in mucosal transmission. PLoS Pathog (2011) 2.32
Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy. J Virol (2003) 2.31
The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A (2009) 2.30
HIV-1 group M conserved elements vaccine. PLoS Pathog (2007) 2.28